Capecitabin e and oxaliplatin (XELOX) in adjuvant therapy of colorectal cancer. Results of the NO16968 (XELOXA) trial

Abstract

Recently published results of the NO16968 (XELOXA) randomized phase III study have shown that capecitabine/oxaliplatin combination is superior to bolus 5-fluorouracil/leucovorin regimens for adjuvant therapy of stage III colon cancer. This trial has also proved for the first time the benefit of adding oxaliplatin to fluoropyrimidines in elderly patients.

Keywords

• Capecitabine
• 5-fluorouracil
• oxaliplatin
• colorectal cancer
• adjuvant therapy